Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Novacyt S.A. (ALNOV.PA)
Le Vésinet, FR
Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A. and its subsidiaries are actively involved in the full lifecycle of diagnostic products, encompassing development, manufacturing, custom design, and global commercialization. These vital diagnostic tools are employed in the detection of both cancer and a variety of infectious diseases. The company boasts an extensive international reach, serving markets throughout the United Kingdom, wider Europe, the United States, the Asia Pacific region, the Middle East, and Africa. Novacyt's operations are structured around three core segments. Primer Design specializes in the creation, production, and sale of molecular real-time qPCR testing devices and reagents, primarily for infectious disease diagnostics. Lab21 Products focuses on developing, manufacturing, and distributing a diverse portfolio of protein-based in-vitro diagnostic (IVD) products, also targeting infectious diseases. The IT-IS International segment is dedicated to engineering and fabricating PCR instruments used in the life sciences and food testing industries. The company's clientele principally includes hospitals and various corporate organizations.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.03% | -1.67% | +84.09% | +46.58% | +36.10% | +50.90% | +2.97% | +26.99% | -85.85% | -60.14% | -93.22% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-10 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 1 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+3.9% Q4'25: +98.7% (vs Q1'24)
-
EPS growth Medical - Devices: +28.5%+44.1% ★ Q4'25: -84.6% (vs Q1'24)
-
FCF margin FCF growth · Medical - Devices: +30.9%-28.7% Q4'25: -32.8% (vs Q1'24)
-
EBIT margin Medical - Devices: +6.2%-64.6% Q4'25: -62.9% (vs Q1'24)
-
ROIC Medical - Devices: +3.3%-90.0% Q4'25: -144.7% (vs Q1'24)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q4'25: +0.0% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-1.27× Q4'25: -0.68× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2013 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.01M
est: 1.08M (-6.6%)
|
6.56M
est: 6.56M (+0.0%)
|
9.44M
est: 9.48M (-0.4%)
|
13.28M
est: 13.24M (+0.3%)
|
12.37M
est: 13.88M (-10.9%)
|
11.18M
est: 16.02M (-30.3%)
|
277.20M
est: 280.87M (-1.3%)
|
95.78M
est: 96.26M (-0.5%)
|
21.04M
est: 71.06M (-70.4%)
|
11.58M
est: 47.42M (-75.6%)
|
19.63M
est: 93.22M (-78.9%)
|
20.40M
est: 19.92M (+2.4%)
|
26.50M
26.50M – 26.50M
+33.0% YoY
|
30.21M
30.21M – 30.21M
+14.0% YoY
|
| EBITDA |
-706.9K
est: -429.4K (-64.6%)
|
-2.02M
est: -2.98M (+32.2%)
|
-3.62M
est: -4.77M (+24.2%)
|
-1.49M
est: -5.28M (+71.8%)
|
-255.0K
est: -6.42M (+96.0%)
|
-991.6K
est: -6.38M (+84.5%)
|
168.24M
est: -111.89M (+250.4%)
|
-4.20M
est: -38.35M (+89.1%)
|
-11.68M
est: -28.31M (+58.8%)
|
-18.24M
est: -18.89M (+3.4%)
|
-34.31M
est: -55.96M (+38.7%)
|
-8.21M
est: -11.96M (+31.3%)
|
-15.91M
-15.91M – -15.91M
-33.0% YoY
|
-18.13M
-18.13M – -18.13M
-14.0% YoY
|
| EBIT |
-820.7K
est: -460.6K (-78.2%)
|
-9.56M
est: -5.05M (-89.5%)
|
-4.46M
est: -13.92M (+68.0%)
|
-2.23M
est: -5.66M (+60.6%)
|
-1.29M
est: -2.45M (+47.5%)
|
-2.44M
est: -6.85M (+64.4%)
|
166.77M
est: -120.03M (+238.9%)
|
-5.54M
est: -41.14M (+86.5%)
|
-19.60M
est: -30.37M (+35.5%)
|
-27.89M
est: -20.27M (-37.6%)
|
-34.31M
est: -63.10M (+45.6%)
|
-13.18M
est: -13.48M (+2.3%)
|
-17.93M
-17.93M – -17.93M
-33.0% YoY
|
-20.45M
-20.45M – -20.45M
-14.0% YoY
|
| Net Income |
-831.8K
est: -17.83M (+95.3%)
|
-10.26M
est: -5.05M (-103.4%)
|
-4.87M
est: -14.68M (+66.8%)
|
-4.83M
est: -4.46M (-8.4%)
|
-4.27M
est: -6.29M (+32.1%)
|
-3.33M
est: -2.10M (-58.7%)
|
132.42M
est: 158.52M (-16.5%)
|
-9.73M
est: 27.61M (-135.2%)
|
-22.20M
est: 25.06M (-188.6%)
|
-28.29M
est: 14.28M (-298.1%)
|
-41.76M
est: 42.20M (-198.9%)
|
-23.31M
est: -10.94M (-113.1%)
|
-8.86M
-8.86M – -8.86M
+19.0% YoY
|
-4.96M
-4.96M – -4.96M
+44.0% YoY
|
| SGA |
—
est: 702.5K (-100.0%)
|
5.22M
est: 6.36M (-18.0%)
|
2.69M
est: 7.02M (-61.7%)
|
9.20M
est: 9.36M (-1.7%)
|
7.73M
est: 8.63M (-10.5%)
|
7.83M
est: 10.44M (-25.0%)
|
8.60M
est: 183.06M (-95.3%)
|
13.84M
est: 62.74M (-77.9%)
|
9.68M
est: 46.31M (-79.1%)
|
5.88M
est: 30.91M (-81.0%)
|
41.53M
est: 75.60M (-45.1%)
|
16.87M
est: 16.15M (+4.5%)
|
21.49M
21.49M – 21.49M
+33.0% YoY
|
24.50M
24.50M – 24.50M
+14.0% YoY
|
| EPS |
-0.28
est: -0.25 (-10.9%)
|
-1.51
est: -0.57 (-166.0%)
|
-0.40
est: -0.16 (-146.5%)
|
-0.21
est: -0.06 (-232.7%)
|
-0.11
est: -0.07 (-54.6%)
|
-0.07
est: 0.02 (-511.7%)
|
1.94
est: 2.24 (-13.6%)
|
-0.14
est: 0.39 (-135.8%)
|
-0.31
est: 0.35 (-187.4%)
|
-0.40
est: 0.20 (-297.9%)
|
-0.59
est: 0.60 (-198.7%)
|
-0.33
est: -0.15 (-113.0%)
|
-0.13
-0.13 – -0.13
+19.0% YoY
|
-0.07
-0.07 – -0.07
+44.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joanne Mason | Chief Scientific Officer & Director | 584.9K | — |
| Steve Gibson | Chief Financial Officer, Company Secretary & Director | 480.4K | male |
| Lyn Dafydd Rees | Chief Executive Officer & Executive Director | 410.1K | male |
| Paul Oladimeji | Group Head of R&D | — | — |
| Peter Coyne | Chief Operations Officer | — | male |
| Wendy Cox | Director of HR | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALNOV.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
